CL2017001438A1 - Antagonistas de miostatina o activina para el tratamiento de sarcopenia - Google Patents

Antagonistas de miostatina o activina para el tratamiento de sarcopenia

Info

Publication number
CL2017001438A1
CL2017001438A1 CL2017001438A CL2017001438A CL2017001438A1 CL 2017001438 A1 CL2017001438 A1 CL 2017001438A1 CL 2017001438 A CL2017001438 A CL 2017001438A CL 2017001438 A CL2017001438 A CL 2017001438A CL 2017001438 A1 CL2017001438 A1 CL 2017001438A1
Authority
CL
Chile
Prior art keywords
sarcopenia
myostatin
treatment
activin antagonists
activine
Prior art date
Application number
CL2017001438A
Other languages
English (en)
Inventor
Dimitris Papanicolaou
David Glass
Patrick Kortebein
Daniel Rooks
Lloyd B Klickstein
Ronenn Roubenoff
Estelle Trifilieff
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024187&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017001438(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2017001438A1 publication Critical patent/CL2017001438A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<p>LA PRESENTE INVENCION SE REFIERE A ANTAGONISTAS DE MIOSTATINA O ACTIVINA, REGIMEN DE DOSIFICACIÔN Y SUS COMPOSICIONES FARMACÉUTICAS, PARA EL TRATAMIENTO DE SARCOPENIA, EN PARTICULAR, SARCOPENIA RELACIONADA CON IA EDAD. ESPECIALMENTE, SE HALLÓ QUE EL ANTAGONISTA DE MIOSTATINA O ACTIVINA BIMAGRUMAB ERA BENEFICIOSO EN EL TRATAMIENTO DE ADULTOS MAYORES CON SARCOPENIA, CON RESPECTO AL AUMERITO DE IA FUERZA Y FUNCION DEL MÜSCULO ESQUELETICO.</p>
CL2017001438A 2014-12-08 2017-06-07 Antagonistas de miostatina o activina para el tratamiento de sarcopenia CL2017001438A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088802P 2014-12-08 2014-12-08

Publications (1)

Publication Number Publication Date
CL2017001438A1 true CL2017001438A1 (es) 2018-02-16

Family

ID=55024187

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017001438A CL2017001438A1 (es) 2014-12-08 2017-06-07 Antagonistas de miostatina o activina para el tratamiento de sarcopenia

Country Status (17)

Country Link
US (1) US20170260275A1 (es)
EP (1) EP3229907A1 (es)
JP (1) JP2017538701A (es)
KR (1) KR20170094292A (es)
CN (1) CN106999589A (es)
AU (2) AU2015358939A1 (es)
BR (1) BR112017011411A2 (es)
CA (1) CA2969800A1 (es)
CL (1) CL2017001438A1 (es)
IL (1) IL252507A0 (es)
MX (1) MX2017007519A (es)
PH (1) PH12017500965A1 (es)
RU (1) RU2017123880A (es)
SG (1) SG11201704094QA (es)
TN (1) TN2017000217A1 (es)
TW (1) TW201627007A (es)
WO (1) WO2016092439A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
ES2595638T3 (es) 2007-09-26 2017-01-02 Chugai Seiyaku Kabushiki Kaisha Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
KR102057826B1 (ko) 2008-04-11 2019-12-20 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2014030750A1 (ja) 2012-08-24 2014-02-27 中外製薬株式会社 マウスFcγRII特異的Fc抗体
SG10201709559PA (en) 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN116284392A (zh) 2016-03-10 2023-06-23 艾科赛扬制药股份有限公司 活化素2型受体结合蛋白及其用途
EP3494991A4 (en) 2016-08-05 2020-07-29 Chugai Seiyaku Kabushiki Kaisha COMPOSITION FOR THE PROPHYLAXIS OR TREATMENT OF IL-8 RELATED DISEASES
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
JOP20190152A1 (ar) * 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
KR101917794B1 (ko) 2018-05-10 2018-11-13 한국과학기술원 진세노사이드 Rh2를 포함하는 근육 질환 개선, 예방 또는 치료용 조성물
KR101966117B1 (ko) 2018-05-25 2019-04-05 (주)녹십자웰빙 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물
KR102017282B1 (ko) 2019-01-28 2019-09-02 (주)녹십자웰빙 가공인삼추출물을 포함하는 근육 분화 촉진용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067616A2 (en) * 2005-12-06 2007-06-14 Amgen Inc Uses of myostatin antagonists
US20070190056A1 (en) * 2006-02-07 2007-08-16 Ravi Kambadur Muscle regeneration compositions and uses therefor
TW201803890A (zh) * 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
US7947646B2 (en) * 2007-03-06 2011-05-24 Amgen Inc. Variant activin receptor polypeptides
PE20120532A1 (es) 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
AR081556A1 (es) * 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
JP6472999B2 (ja) * 2011-07-01 2019-02-20 ノバルティス アーゲー 代謝障害を治療するための方法
NZ703724A (en) * 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
HK1219280A1 (zh) * 2013-08-14 2017-03-31 Novartis Ag 治疗偶发性包涵体肌炎之方法
TW201622746A (zh) * 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法

Also Published As

Publication number Publication date
IL252507A0 (en) 2017-07-31
KR20170094292A (ko) 2017-08-17
TW201627007A (zh) 2016-08-01
PH12017500965A1 (en) 2017-10-18
CN106999589A (zh) 2017-08-01
AU2019200082A1 (en) 2019-01-31
MX2017007519A (es) 2017-08-22
AU2015358939A1 (en) 2017-06-15
WO2016092439A1 (en) 2016-06-16
SG11201704094QA (en) 2017-06-29
EP3229907A1 (en) 2017-10-18
RU2017123880A3 (es) 2019-08-29
TN2017000217A1 (en) 2018-10-19
JP2017538701A (ja) 2017-12-28
BR112017011411A2 (pt) 2018-02-14
RU2017123880A (ru) 2019-01-10
US20170260275A1 (en) 2017-09-14
CA2969800A1 (en) 2016-06-16

Similar Documents

Publication Publication Date Title
CL2017001438A1 (es) Antagonistas de miostatina o activina para el tratamiento de sarcopenia
CL2016001933A1 (es) Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
SV2017005426A (es) Derivados de feniltriazol sustituido con hidroxialquilo y sus usos
MX2017001752A (es) Indoles para su uso en la infección por el virus de la gripe.
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
MA48448A (fr) Dérivés de quinazoline utilisés pour traiter le vih
MA40943A (fr) Pyrrolopyridines substituées utilisées en tant qu&#39;inhibiteurs de bromodomaines
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
MA40940A (fr) Pyrrolopyridines substituées utilisées en tant qu&#39;inhibiteurs de bromodomaines
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
CL2016001963A1 (es) Heteroarilos inhibidores de syk
MX2016003216A (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
MX2016015724A (es) Derivados del colano para uso en el tratamiento y/o prevencion de enfermedades en las que intervienen el fxr y el tgr5/gpbar1.
DK3125883T3 (da) Indolderivater til anvendelse i medicin
DK3229810T3 (da) Phospholipid-ether-analoger som kræftrammende lægemiddelvehikler
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
CL2017000391A1 (es) Nitrógeno tricíclico que contiene compuestos para el tratamiento de una infección por neisseria gonorrhoea
MX377534B (es) Compuestos para usarse en el tratamiento de hiperinsulinemia.
BR112016023494A2 (pt) método, aparelho e mídia legível por computador para gerar um conjunto de produtos ortopédicos recomendados.
DOP2016000212A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
TWD174815S (zh) 瓶子
CL2016002562A1 (es) Régimen de dosificación de liberación inmediata de moduladores s1p.
EA201790392A1 (ru) Фармацевтическая упаковка